Use of Master Files in Supporting Device-Drug Approvals Use of Master Files in Supporting Device-Drug Approvals This article provides a comprehensive step-by-step guide focused on the use of master files in the approval of combination products in the US, emphasizing actionable insights aligned with FDA regulations. Step 1: Understanding Combination Products and Their Regulatory Framework Combination products are defined as therapeutic and diagnostic products that combine drugs, devices, or biological products. They are regulated under a unique framework within the FDA that aims to ensure comprehensive oversight. This step involves understanding the critical concepts of the Product’s Primary Mode of…

FDA OTC Switch Risk Mitigation Strategy for US Sponsors in – Insight 6 FDA OTC Switch Risk Mitigation Strategy for US Sponsors in – Insight 6 The transition of a prescription drug to an over-the-counter (OTC) drug status presents unique regulatory challenges and opportunities for sponsors. This article outlines a step-by-step approach to successfully navigate the FDA’s OTC switch process, focusing on risk mitigation strategies essential for US sponsors in . The article is structured as a practical guide, aimed at professionals in Regulatory Affairs, Market Access, Quality Assurance, and Commercial Strategy, helping you understand the detailed requirements and processes…

Common Challenges in Submitting Combination Product Applications Common Challenges in Submitting Combination Product Applications Submitting applications for combination products is a complex undertaking fraught with challenges that regulatory affairs professionals must navigate carefully. This guide offers a step-by-step tutorial on successfully handling the regulatory landscape surrounding FDA combination product consulting, focusing on practical actions and documentation expectations for submissions under 21 CFR Part 4. Step 1: Understanding FDA Definitions and Classifications The first step in addressing the challenges of submitting combination product applications is to comprehend the FDA’s definitions and classifications. A combination product can be classified as a drug-device…

FDA OTC Switch Risk Mitigation Strategy for US Sponsors in 2023 – Insight 5 FDA OTC Switch Risk Mitigation Strategy for US Sponsors in 2023 – Insight 5 The transition of products from prescription (Rx) to over-the-counter (OTC) status represents a significant regulatory milestone for pharmaceutical companies. Understanding and implementing an effective OTC switch involves navigating complex regulations and requirements. This guide provides a detailed step-by-step tutorial to help US sponsors effectively strategize and execute the Rx to OTC switch consulting process, with a focus on the FDA’s risk mitigation strategies in 2023. Step 1: Understanding the Regulatory Framework for…

Postmarket Safety Reporting for Combination Products (FDA Final Rule) Postmarket Safety Reporting for Combination Products (FDA Final Rule) The regulation of combination products, as defined under 21 CFR Part 3, has evolved significantly to address both drug and device safety concerns in the postmarket phase. This article serves as a comprehensive, step-by-step tutorial on the final rule issued by the FDA regarding postmarket safety reporting for combination products. The objective is to clarify the processes, documentation expectations, and practical actions required by regulatory professionals in the United States. Each section of this guide will comprehensively cover the applicable requirements and…

Human Factors Engineering in Combination Product Approvals Human Factors Engineering in Combination Product Approvals As the pharmaceutical and medical device landscape evolves, comprehensive understanding of Human Factors Engineering (HFE) in combination product approvals becomes essential. This tutorial guide provides a systematic approach for regulatory professionals involved in FDA combination product consulting, focusing on the nuances of HFE in the lifecycle of combination products. With a clear understanding of the regulatory expectations set forth by the FDA, stakeholders can better design, evaluate, and submit combination products that effectively incorporate human factors considerations. Step 1: Understanding Regulatory Definitions and Framework The first…

FDA OTC Switch Risk Mitigation Strategy for US Sponsors in 2023 – Insight 4 FDA OTC Switch Risk Mitigation Strategy for US Sponsors in 2023 – Insight 4 The transition of a prescription (Rx) drug to over-the-counter (OTC) status is a nuanced process requiring careful planning and execution. This strategic guide outlines the essential steps for US sponsors to effectively navigate the FDA OTC switch regulations in 2023. Emphasis is placed on risk mitigation strategies, documentation expectations, and compliance with FDA guidelines. Adhering to these stipulations can assist sponsors in addressing potential challenges while accelerating market access. Step 1: Understanding…

Quality Considerations: Bridging Design Controls and Drug GMPs Quality Considerations: Bridging Design Controls and Drug GMPs In the regulatory landscape of combination products, particularly those involving companion diagnostics, aligning design controls with Good Manufacturing Practices (GMPs) for drugs is critical. This article serves as a step-by-step tutorial on how to effectively navigate the complexities of companion diagnostic regulatory consulting. The focus will be on the intersection of design controls and drug GMPs, ensuring compliance with relevant regulations such as 21 CFR Part 4. This guide is geared towards regulatory affairs professionals, QA specialists, and product teams engaged in the development…

FDA OTC Switch Risk Mitigation Strategy for US Sponsors in 2023 – Insight 3 FDA OTC Switch Risk Mitigation Strategy for US Sponsors in 2023 – Insight 3 The transition of prescription (Rx) medications to over-the-counter (OTC) status can provide substantial commercial benefits and increase patient accessibility. However, this switch entails a thorough understanding of the associated regulatory pathways and risk mitigation strategies required by the U.S. Food and Drug Administration (FDA). This guide provides a comprehensive step-by-step tutorial on the FDA OTC switch risk mitigation strategy for U.S. sponsors, focusing on essential actions, required documentation, and potential pitfalls. This…

Case Study: Regulatory Approval of an Inhaler-Based Combination Product Case Study: Regulatory Approval of an Inhaler-Based Combination Product Inhaler-based combination products represent a complex intersection of pharmaceuticals and medical devices, necessitating a comprehensive understanding of regulatory pathways, documentation, and compliance provisions. This guide details the step-by-step process for navigating the regulatory framework of the FDA for these products with a focus on inhalers as combination products. Step 1: Understanding Combination Products Combination products are defined by the FDA as products that combine a drug, device, or biological product. Inhalers, which deliver medications in aerosol form, often combine drug components with…